Lumida
/GOSS
⌘K
Gossamer Bio Inc

Gossamer Bio Inc

GOSS
$0.18USD+13.12%+0.02 today

MARKET CAP

85.5M

P/E (TTM)

FWD P/E

DAY RANGE

$0 – $0

52W RANGE

$0
$4

AI Summary

Stalk
Sell NowMedium

GOSS remains in a Stage 4 decline with both long- and short-term downtrends intact. Price continues to trade below the 9, 21, 50, and 200 EMAs, with repeated rejections at those levels. The active Post-Capitulation pattern shows forced selling has exhausted but no base has formed, reinforcing a bearish medium-term stance. Short-term momentum and EMA rejection favor immediate downside participation, warranting a sell-now posture despite oversold context.

  • NDA submission scheduled for Sept 2026, potential FDA approval by 2027.
  • Q1 2026 cash and equivalents ~$99 M, runway into early 2027.
  • Q1 2026 net loss $36.6 M strains cash flow and operations.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2024FY 2025TREND
Sales, Adj.$114.7M$48.5M
YoY %-57.7%
P / Sales1.8x14.6x
EV / Sales3.9x19.9x
Gross Profit, Adj.$114.7M$48.5M
YoY %-57.7%
Margin %100.0%100.0%
EV / Gross Profit3.9x19.9x
EBITDA, Adj.$-68.8M$-177.0M
YoY %+63.5%-157.2%
Margin %-60.0%-365.2%
EV / EBITDA-6.5x-5.5x
EBIT$-59.9M$-170.7M
YoY %+67.4%-184.9%
Margin %-52.2%-352.2%
EV / EBIT-7.4x-5.7x
Net Income$-56.5M$-170.4M
YoY %+68.6%-201.4%
Net Margin-49.3%-351.5%
EPS (GAAP)-$0.25-$0.75
YoY %+78.8%-200.0%